Nkarta Reports Third Quarter 2026 Financial Results and Provides Business Update

On November 5, 2026 Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, reported financial results for the third quarter ended September 30, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"NKX019 is advancing in our two lead indications, myositis and systemic sclerosis," said Paul J. Hastings, Chief Executive Officer of Nkarta. "We’re delighted to have been selected to present our initial clinical data in two oral presentations and one poster presentation at ACR Convergence 2026 in Orlando. We believe that the safety profile of engineered CAR-NK cells could broaden cell therapy access to reach far more patients. With off-the-shelf availability and outpatient dosing at a growing network of community-based sites, our program is designed to deliver on that potential."

NKX019 Clinical Program Progress and Upcoming Milestones

•
Initial clinical data from the Ntrust program to be presented at ACR Convergence 2026 in the company’s lead indications: idiopathic inflammatory myopathy and systemic sclerosis. Presentations include an oral presentation in myositis on November 8, a poster in systemic sclerosis on November 9, and an oral presentation of safety data across autoimmune indications on November 11.
•
Enrollment continues in the Ntrust program, our multi-center, open-label, dose-escalation clinical trials evaluating NKX019 in multiple autoimmune diseases.
•
Outpatient dosing is underway within our network of community-based sites, extending access to patients who cannot travel to academic medical centers.
•
Patients are being dosed at 4 billion cells per dose x 3 doses (12 billion cells total) across all indications in Ntrust-1 and Ntrust-2.

Third Quarter 2026 Financial Highlights

•
Nkarta had cash, cash equivalents, restricted cash, and investments in marketable securities of $216.0 million as of September 30, 2026.
•
Research and development (R&D) expenses were $29.5 million for the third quarter of 2026. Non-cash stock-based compensation expense included in R&D expense was $0.7 million for the third quarter of 2026.
•
General and administrative (G&A) expenses were $6.3 million for the third quarter of 2026. Non-cash stock-based compensation expense included in G&A expense was $1.1 million for the third quarter of 2026.
•
Net loss was $33.3 million, or $0.45 per basic and diluted share, for the third quarter of 2026. This net loss includes non-cash charges of $2.8 million that consisted primarily of share-based compensation and depreciation expenses.

Financial Guidance

•
Nkarta expects its current cash and cash equivalents to fund its current operating plan into 2029.

About the Ntrust℠ Clinical Trials in Autoimmune Disease

Ntrust-1 (NCT06557265) and Ntrust-2 (NCT06733935) are multi-center, open-label, dose-escalation clinical trials in patients with autoimmune disease receiving lymphodepletion followed by CD19-targeted CAR-NK cell therapy. Both trials assess the safety of NKX019 in people living with autoimmune diseases as well as its potential to achieve durable remission via a "reset" of the immune system through the elimination of pathogenic B cells.

The Ntrust trials are enrolling up to 12 patients per dose level per disease indication, with leading indications in myositis and systemic sclerosis, as well as ANCA-associated vasculitis, rheumatoid arthritis, lupus nephritis, and primary membranous nephropathy. Additional patients may be enrolled if needed to refine patient populations for further study.

In both studies, patients receive a three-dose cycle of NKX019 following lymphodepletion with fludarabine and cyclophosphamide or cyclophosphamide alone, if they have significant cytopenia at baseline. This approach is designed to evaluate the single-agent activity of NKX019 and facilitate a more rapid path to regulatory approval. Patients in both trials may also receive additional cycles, if needed, to restore response or enable a deeper response.

About NKX019

NKX019 is an allogeneic, cryopreserved, off-the-shelf immunotherapy candidate that uses natural killer (NK) cells derived from the peripheral blood of healthy adult donors. It is engineered with a humanized CD19-directed chimeric antigen receptor (CAR) for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease. Nkarta is evaluating NKX019 in multiple autoimmune conditions.

(Press release, Nkarta, NOV 5, 2026, View Source [SID1234674319])

aTyr Pharma Announces Third Quarter 2026 Results and Provides Corporate Update

On November 5, 2026 aTyr Pharma, Inc. (Nasdaq: ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, reported third quarter 2026 results and provided a corporate update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"During the last quarter we reached alignment with the U.S. Food and Drug Administration (FDA) on the protocol for a Phase 3 study of our lead therapeutic candidate, efzofitimod, in pulmonary sarcoidosis patients with restrictive lung disease, a major form of interstitial lung disease (ILD) with a high unmet medical need," said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. "We believe the efzofitimod program is well-positioned, considering the late-stage development status in an indication with a multi-billion-dollar global market opportunity, and have determined that at this time the best way for us to advance efzofitimod is to prioritize strategic partnerships."

Third Quarter 2026 and Subsequent Period Highlights

Reached alignment with the FDA on the protocol for a global Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease. The Company recently initiated study-related activities for the trial and is prioritizing strategic partnerships and/or licensing arrangements in order to advance the Phase 3 study beyond the completion of the initial study-related activities.
Completed enrollment in the Phase 2 EFZO-CONNECT study of efzofitimod in patients with limited or diffuse systemic sclerosis (SSc)-related ILD (SSc-ILD). Full study results are expected in the second quarter of 2027. These will include data for multiple study endpoints, including the modified Rodnan Skin Score, skin histopathology, gene expression profiling, immune biomarkers, forced vital capacity, and an exposure response analysis.
Published the results of the Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis in The Lancet Respiratory Medicine. The peer-reviewed publication reinforces efzofitimod’s differentiated profile and potential to advance pulmonary sarcoidosis care. The publication is available on the Company’s website.
Published a manuscript demonstrating the mechanism of action and anti-fibrotic effects of ATYR0101 in the Journal of Biological Chemistry. ATYR0101 is a fusion protein that interacts with latent transforming growth factor beta binding protein 1 (LTBP-1) through a unique way that presents a differentiated approach to targeting fibrosis. The publication is available on the Company’s website.
Announced a research collaboration for pediatric osteosarcoma with Montefiore Einstein involving preclinical studies of ATYR2810, the Company’s monoclonal antibody that targets the neuropilin-2 (NRP2) receptor. The collaboration is to further the development and testing of ATYR2810 in an aggressive cancer where NRP2 is implicated.
Third Quarter 2026 Financial Highlights and Cash Position

Cash & Investment Position: Cash, cash equivalents, restricted cash and available-for-sale investments as of September 30, 2026, were $50.3 million. Based on its current cash and operating expense forecast and plans, the Company anticipates that this cash position will be sufficient to fund the Company’s current operations into late 2028.
R&D Expenses: Research and development expenses were $10.4 million for the third quarter 2026, which consisted primarily of costs for the Phase 2 EFZO-CONNECT study and research and development costs for the Company’s preclinical product candidates.
G&A Expenses: General and administrative expenses were $8.3 million for the third quarter 2026.
About Efzofitimod

Efzofitimod is a novel biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 to resolve inflammation without immune suppression and potentially prevent the progression of fibrosis. Efzofitimod is currently being investigated in the Phase 2 EFZO-CONNECT study in patients with systemic sclerosis (SSc, or scleroderma)-related ILD, and aTyr recently initiated study-related activities for a global Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis, a major form of ILD. These forms of ILD have limited therapeutic options and there is a need for safer and more effective, disease-modifying treatments that improve outcomes.

(Press release, aTyr Pharma, NOV 5, 2026, View Source [SID1234674347])

Zai Lab Presents Updated Clinical Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Clinically Meaningful Responses and a Manageable Safety Profile in Previously Treated Extrapulmonary Neuroendocrine Carcinomas

On November 5, 2026 Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma company, reported that updated data from a Phase 1b/2 trial of zocilurtatug pelitecan (zoci, formerly ZL-1310), a DLL3-targeting antibody-drug conjugate (ADC), will be shared tomorrow at the North American Neuroendocrine Tumor Society (NANETS) 2026 Multidisciplinary NET Medical Symposium in Las Vegas. The data indicate that zoci demonstrated clinically meaningful, durable anti-tumor responses in patients with previously treated advanced extrapulmonary neuroendocrine carcinomas (epNECs), aggressive cancers that arise outside the lung and share biological characteristics with small cell lung cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

There is currently no established standard of care for patients with epNECs who progress on or after first-line platinum-based chemotherapy. Chemotherapy regimens commonly used in clinical practice have limited efficacy, particularly in gastroenteropancreatic NEC (GEP-NEC), and outcomes remain poor.1

"Given the aggressiveness of epNECs and the relatively limited treatment options following platinum-based chemotherapy, patients who have advanced or metastatic disease need additional options," said Amr Mohamed, M.D., study investigator and Director of the Neuroendocrine Tumor Program at UH Seidman Cancer Center, University Hospitals and Case Western Reserve University. "The efficacy and safety data from this trial are encouraging and underscore the possibility that zoci could play a key role in a new standard of care for patients with epNEC."

Updated data from the Phase 1b/2 clinical trial of zoci (NCT06885281) showed clinically meaningful responses in patients with advanced or metastatic epNECs that had progressed on or after platinum-based chemotherapy. The study evaluated zoci administered intravenously as monotherapy at 1.6 mg/kg every three weeks. Tumor response was evaluated by investigator-assessed RECIST v1.1 with additional assessments for some NECs.

In the study’s primary efficacy population of 60 patients by the data cutoff, investigator-assessed confirmed ORR was 40.0% (24/60; 95% CI: 27.6%-53.5%), and disease control rate was 55.0% (33/60, 95% CI: 41.6%-67.9%).
Treatment with zoci decreased tumor sizes in multiple epNEC subtypes: Confirmed ORR was 35.9% (14/39, 95% CI: 21.2%-52.8%) in GEP-NEC and 47.6% (10/21, 95% CI: 25.7%-70.2%) in other epNECs.
Overall median duration of response (mDOR) was 5.6 months (95% CI: 3.0-9.3).
Among 18 responders with at least 6 months of opportunity for follow-up from initial response, 6 (33.3%) remain in response or had a response lasting 6 months or longer.
Zoci demonstrated a manageable safety profile: Among all 133 patients in the study, 12.8% (17/133) experienced Grade ≥3 treatment-related adverse events (TRAEs) and 29.3% (39/133) experienced Grade ≥3 treatment-emergent adverse events (TEAEs), with anemia (7/133, 5.3%) and neutropenia (5/133, 3.8%) as the highest Grade ≥3 TEAEs. Grade 2 interstitial lung disease (ILD)/pneumonitis was reported in 2 patients (1.5%), with no Grade ≥3 ILD events observed. Treatment related discontinuation occurred in 1/133 (0.8%) patients; only one Phase 2 participant experienced a fatal TEAE, determined by the investigator to be unrelated to the study drug.
Efficacy results from this larger dataset are consistent with those previously reported at AACR (Free AACR Whitepaper) 2026. Data from patients recently enrolled in Phase 2 is not yet sufficiently mature for analysis, and follow-up is ongoing. Additional data is expected in 2027.

DLL3 expression was assessed by immunohistochemistry. Antitumor activity was observed across the spectrum of DLL3 expression levels, including in patients with low or absent DLL3 expression.

"We are increasingly excited about the potential of zoci to provide an important new targeted therapeutic option for patients with multiple cancer types that commonly express DLL3, including epNECs," said Rafael G. Amado, M.D., President, Head of Global Research and Development at Zai Lab. "We are pleased that results from this larger dataset, with longer follow-up, are consistent with the earlier data we shared at AACR (Free AACR Whitepaper). A confirmed objective response rate of 40 percent, including response in multiple epNEC subtypes, with anti-tumor activity observed over time and a treatment related discontinuation rate of less than one percent, are encouraging signals for patients who have few treatment options following platinum-based chemotherapy. We are pursuing an accelerated approval pathway for zoci in previously treated epNECs and will continue to advance our clinical programs for this disease with urgency."

Zai Lab has completed enrollment in the Phase 2 second-line expansion cohort of the Phase 1b/2 zoci monotherapy trial. Based on feedback from the U.S. Food and Drug Administration (FDA), the company will pursue a potential accelerated approval pathway based on this single-arm expansion study with topline data expected in 2027. Zai Lab also intends to initiate a global Phase 3 first-line maintenance trial of zoci monotherapy in epNECs next year.

In August, the U.S. FDA granted Orphan Drug Designation (ODD) to zoci for the treatment of NECs, following receipt of ODD for zoci in pulmonary NECs from the European Medicines Agency. The U.S. FDA previously granted Fast Track designation (FTD) to zoci for EP-NECs, as well as FTD and ODD to zoci for SCLC.

NANETS 2026 zoci presentation details:

Abstract title: Phase 1b/2 Study of Zocilurtatug Pelitecan in Patients with Advanced Extrapulmonary Neuroendocrine Carcinomas (epNEC)

Abstract ID: 36547

Presenter: Amr Mohamed, M.D.

Date/time: Friday, November 6, 2026, 9:34–9:46 AM PT

Session/location: Featured Abstracts 2: Emerging Strategies in High-Grade and Advanced NENs

Notes:

1 Sorbye H, Hjortland GO, Vestermark LW, et al. Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study. British Journal of Cancer. 2025;133:316-324. doi:10.1038/s41416-025-03054-w

About Zocilurtatug Pelitecan (zoci, formerly ZL-1310)

Zoci is a novel, potential first-in-class antibody-drug conjugate (ADC), that targets Delta-like ligand 3 (DLL3), a validated therapeutic target that is overexpressed in small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs), including extrapulmonary NECs, making it a promising target for the treatment of these aggressive, lethal and difficult-to-treat malignancies. The DLL3 antigen is generally associated with poor clinical outcomes.

Zoci remains on track to become Zai Lab’s first global oncology launch. In addition to the Phase 3 combination trial in first-line extensive stage SCLC that Zai Lab is advancing toward initiation, the Company is also conducting the Phase 3 DLLEVATE study evaluating zoci in previously treated extensive stage SCLC (ES-SCLC) vs. physician’s choice of chemotherapy, and a Phase 1/2 trial in neuroendocrine carcinomas and other DLL3-positive solid tumors. Data presented at ESMO (Free ESMO Whitepaper) 2026 from an ongoing global Phase 1b trial in first-line ES-SCLC showed that zoci 1.6 mg/kg plus atezolizumab achieved a confirmed ORR of 81.8% (27/33), 6 months PFS 81.9% and was well tolerated, with Grade ≥ 3 adverse events related to zoci in 9.1% (3/33) of patients. Earlier data presented at AACR (Free AACR Whitepaper) 2026 from the monotherapy part of the same Phase 1 trial in previously-treated ES-SCLC demonstrated that zoci achieved meaningful intracranial efficacy, including in patients who have not received radiotherapy to the brain.

Earlier this year, Zai Lab entered into a global clinical trial collaboration with Amgen to evaluate zoci in combination with Amgen’s IMDELLTRA (tarlatamab-dlle), a DLL3/CD3 bispecific T-cell engager (TCE), for ES-SCLC, and a clinical collaboration with Boehringer Ingelheim to evaluate zoci in combination with obrixtamig, a DLL3/CD3 bispecific TCE, for ES-SCLC and other NECs.

(Press release, Zai Laboratory, NOV 5, 2026, View Source [SID1234674363])

Celcuity Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update

On November 5, 2026 Celcuity Inc. (Nasdaq: CELC), a commercial-stage biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, reported financial results for the third quarter ended September 30, 2026, and other recent business developments.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Celcuity announced on September 30, 2026, that REVTORPYK (gedatolisib) became commercially available in the United States for use in combination with fulvestrant, with or without palbociclib, for the treatment of HR+/HER2- locally advanced or metastatic breast cancer ("ABC") without a PIK3CA mutation detected following progression on or after at least one line of endocrine therapy in the metastatic setting.

"Our commercial and medical affairs teams have laid the foundation for a strong launch over the past few years, and their efforts are paying off," said Brian Sullivan, CEO and co-founder of Celcuity. "Physicians are enthusiastic and eager to treat their patients with REVTORPYK, and we are pleased with their interest in getting eligible patients on treatment in the initial weeks since we launched."

"We estimate over 90% of commercial and Medicare lives are in health plans that cover REVTORPYK. The unprecedented efficacy results from the wild-type cohort of the pivotal VIKTORIA-1 study, and the preferred Category 1 recommendation in the NCCN Guidelines, provide physicians with a compelling value proposition to address a significant unmet need for the tens of thousands of patients affected each year by HR+/HER2-, PIK3CA wild-type advanced breast cancer."

Business Highlights and Other Recent Developments

2nd Line HR+/HER2- ABC – PIK3CA wild-type

•
FDA approval. On July 14, 2026, the US Food and Drug Administration ("FDA") approved REVTORPYK for the treatment of patients with HR+/HER2- ABC without a PIK3CA mutation detected following progression on or after at least one line of endocrine therapy in the metastatic setting.
•
NCCN preferred Category 1 recommendation. On July 30, 2026, NCCN included REVTORPYK as a preferred Category 1 recommendation for second-line and/or subsequent-line therapy for the treatment of patients with HR+/HER2- advanced breast cancer without a PIK3CA mutation following progression on or after at least one line of endocrine therapy.
•
Early launch off to a positive start. 78% of the top 36 strategic accounts, representing ~50% of the total addressable patient population, have ordered REVTORPYK. Over 3,400 sites, many of which are affiliated with one of the top 36 strategic accounts, have directly engaged with Celcuity oncology sales specialists. These sites treat 82% of breast cancer patients. Additionally, over 1,100 health care providers have attended REVTORPYK educational programs.
•
Broad payor coverage and major provider pathway inclusion. 91% of U.S. commercial and Medicare lives are in health plans that cover REVTORPYK, and REVTORPYK has already been incorporated in 3 of the 4 largest health care provider pathways.
2nd Line HR+/HER2- ABC – PIK3CA mutant-type

In October, updated results from the Phase 3 VIKTORIA-1 study were presented in a late breaking rapid oral presentation at the European Society for Medical Oncology ("ESMO") Congress 2026. Key results included:

•
Median progression-free survival ("PFS") was 21.5 months with the gedatolisib triplet (gedatolisib + fulvestrant + palbociclib) and 11.5 months with the gedatolisib doublet (gedatolisib + fulvestrant) versus 9.1 months with alpelisib + fulvestrant in patients who had no liver metastases.

•
Objective response rate ("ORR") and median duration of response for patients with evaluable disease were 59% and 19.4 months, respectively, for the gedatolisib triplet and 43% and 27.8 months, respectively, for the gedatolisib doublet, compared to 33% and 7.5 months, respectively, for alpelisib + fulvestrant.
•
The discontinuation rate for gedatolisib due to adverse events was 5% and 4% with the gedatolisib triplet and doublet, respectively, compared to 19% for alpelisib + fulvestrant.
Based on the positive data from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 study, Celcuity submitted a supplemental New Drug Application ("sNDA") to the FDA in the third quarter of 2026. Celcuity expects to submit VIKTORIA-1 Phase 3 data for both the wild-type and mutant cohorts to global regulatory authorities later this year or early next year.

1st Line HR+/HER2- ABC

•
VIKTORIA-2. Enrollment is ongoing in the Phase 3 VIKTORIA-2 clinical trial that is evaluating gedatolisib combined with palbociclib and fulvestrant in the first-line setting for patients with endocrine resistant HR+/HER2- ABC (Study 1) or gedatolisib combined with palbociclib and letrozole in the first-line setting for patients with endocrine sensitive HR+/HER2- ABC (Study 2).
Metastatic Castration-Resistant Prostate Cancer ("mCRPC")

Updated data from a Phase 1b/2 study evaluating gedatolisib plus darolutamide in men with mCRPC were presented at a poster session at the ESMO (Free ESMO Whitepaper) Congress 2026. Key results included:

•
Median radiographic progression free survival ("rPFS") was 15.7 months and the six-month rPFS rate ("rPFS6") was 82.2% in patients with prior exposure to abiraterone. Median rPFS was 9.1 months and rPFS6 was 62.5% in patients with prior exposure to enzalutamide.
•
Prostate-specific antigen ("PSA") ≥50% decreases from baseline were observed across all dose levels; response rates were 36%, 47% and 67% at the 120-, 180-, and 240-mg gedatolisib dose levels, respectively, in patients with prior exposure to either abiraterone or enzalutamide.
•
Gedatolisib plus darolutamide demonstrated a manageable safety profile across the evaluated dose levels (120 mg, 180 mg, 240 mg) with one dose-limiting toxicity (Grade 3 rash), no Grade 4/5 treatment-related adverse events ("TRAEs"), and no TRAEs leading to treatment discontinuation or death. Grade 3 TRAEs occurred in 20% of patients with only rash and pruritus occurring in more than one patient.
•
The randomized Phase 2 study to evaluate the efficacy and safety of, and determine the recommended Phase 3 dose level of, gedatolisib in combination with darolutamide in patients with prostate cancer is expected to begin in the first half of 2027.
New Senior Management

Byron Robinson, Ph.D., J.D., joined Celcuity as Chief Strategy Officer to support development of strategic clinical and business development plans. Byron has served for more than 30 years in a variety of executive roles with responsibility for drug discovery, global clinical development, program leadership, portfolio strategy, market intelligence and competitive analytics. His experience includes senior executive roles at both small and large biotech and pharma companies including Janux Therapeutics, Merck KGaA, Bayer AG, and Amgen.

Third Quarter 2026 Financial Results

Unless otherwise stated, all comparisons are for the third quarter ended September 30, 2026, compared to the third quarter ended September 30, 2025.

Net loss for the third quarter of 2026 was $73.3 million, or $1.33 per share, compared to a net loss of $43.8 million, or $0.92 per share, for the prior year period. Non-GAAP adjusted net loss for the third quarter of 2026 was $66.8 million, or $1.21 per share, compared to non-GAAP adjusted net loss of $37.2 million, or $0.78 per share, for the prior year period. Non-GAAP adjusted net loss excludes stock-based compensation expense, non-cash interest expense and non-cash investment income. Because these items have no impact on Celcuity’s cash position, management believes non-GAAP adjusted net loss better enables Celcuity to focus on cash used in operations. For a reconciliation of financial measures calculated in accordance with generally accepted accounting principles in the United States ("GAAP") to non-GAAP financial measures, please see the financial tables at the end of this press release.

Shipments of REVTORPYK commenced on September 30, 2026. We recognize revenue when control of REVTORPYK transfers to the healthcare providers or pharmacies, which generally occurs upon delivery. Because no product was received by the healthcare providers or pharmacies until after September 30, 2026, we did not recognize any product revenue during the third quarter ended September 30, 2026.

Total operating expenses were $77.3 million for the third quarter of 2026, compared to $42.8 million for the prior year period.

Research and development ("R&D") expenses were $37.5 million for the third quarter of 2026, compared to $30.4 million for the prior year period. The $7.1 million increase in R&D expenses was primarily due to a $5.3 million increase in employee-related and consulting expenses, of which $1.5 million related to stock-based compensation, and a $2.1 million increase in manufacturing and other costs. These increases were partially offset by a $0.3 million decrease in clinical trial costs.

Selling, general and administrative ("SG&A") expenses were $39.8 million for the third quarter of 2026, compared to $12.4 million for the prior year period. The $27.4 million increase in SG&A expenses was primarily due to a $14.4 million increase in employee-related expenses, of which $1.7 million related to stock-based compensation. The increase in employee-related expenses was primarily driven by the hiring of additional personnel to support the commercialization of REVTORPYK. The remaining $13.0 million increase was primarily due to an $11.1 million increase in costs to support the commercialization of REVTORPYK, including consulting expenses and expanding infrastructure costs, and a $1.9 million increase in other administrative expenses. In the aggregate, $25.3 million of the $27.4 million SG&A increase related to commercial headcount additions and other activities to support the commercialization of REVTORPYK.

Net cash used in operating activities for the third quarter of 2026 was $66.2 million, compared to $44.8 million for the prior year period. In addition, we made a $50.0 million payment to Pfizer triggered by receipt of FDA approval for REVTORPYK per our exclusive global license agreement for gedatolisib. Cash, cash equivalents and short-term investments were $642.7 million at the end of the third quarter of 2026. We expect that our current cash, cash equivalents and short-term investments will finance our operations through 2029.

Webcast and Conference Call Information

To participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-1865.

A live webcast presentation can also be accessed using this weblink: View Source;tp_key=e66abcfe8a. A replay of the webcast will be available on the Celcuity website following the live event.

About REVTORPYK (gedatolisib)

REVTORPYK (gedatolisib) is a kinase inhibitor indicated in combination with fulvestrant, with or without palbociclib, for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting.

Please click here for Important Safety Information and Full Prescribing Information for REVTORPYK.

(Press release, Celcuity, NOV 5, 2026, View Source [SID1234674389])

Lantheus Reports Third Quarter 2026 Financial Results

On November 5, 2026 Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, reported financial results for its third quarter ended September 30, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition, and as previously announced, Lantheus entered into a definitive agreement on August 3, 2026 to merge with Curium under which Curium US Holdings LLC will acquire all outstanding shares of Lantheus for $102.50 per share in cash at closing, plus non-transferable Contingent Value Rights ("CVRs") providing for up to $12.00 per share in potential additional cash payments, subject to achievement of specified commercial milestones for Lantheus’ products through 2030. The transaction represents a total per share consideration of up to $114.50 and a total transaction value of up to approximately $8.0 billion. Together, Curium and Lantheus are positioned to create a radiopharmaceutical company spanning diagnostics and therapeutics, with the infrastructure and capabilities to serve patients in more than 70 countries. The Board of Directors of Lantheus has unanimously approved the transaction. Additional information regarding the transaction is available in the Company’s Current Report on Form 8-K filed with the SEC on August 4, 2026.

In connection with the pending transaction, Lantheus is suspending its previously issued full year 2026 financial guidance and will not be hosting a conference call in connection with its third quarter 2026 results.

Summary Financial Results

Three Months Ended
September 30,
(in millions, except per share data – unaudited) 2026 2025 % Change
Worldwide revenue $ 389.9 $ 384.0 1.5 %
GAAP net income $ 22.4 $ 27.8 (19.4 %)
GAAP fully diluted earnings per share $ 0.33 $ 0.41 (19.5 %)
Adjusted net income (non-GAAP) $ 115.1 $ 85.7 34.3 %
Adjusted fully diluted earnings per share (non-GAAP) $ 1.68 $ 1.27 32.3 %

Third Quarter 2026

Worldwide revenue increased 1.5% to $389.9 million compared to the same period in 2025.
Sales of PYLARIFY were $238.9 million, a decrease of 0.7%.
Sales of Neuraceq were $45.6 million, an increase of 123.0%.
Sales of DEFINITY were $85.7 million, an increase of 4.8%.
Operating income decreased 26.2% to $32.2 million. Adjusted operating income (non-GAAP) increased 28.1% to $153.2 million.
Fully diluted earnings per share decreased 19.5% to $0.33, compared to fully diluted earnings per share of $0.41 in the prior year period. Adjusted fully diluted earnings per share (non-GAAP) increased 32.3% to $1.68, compared to $1.27 in the prior year period.
Net cash provided by operating activities and free cash flow were $102.0 million and $99.9 million, respectively.

Balance Sheet

At September 30, 2026, the Company’s cash and cash equivalents were $683.6 million, compared to $359.1 million at December 31, 2025.
The Company currently has access to up to $750.0 million from a revolving line of credit.

Recent Business Highlights

Received CMS Transitional Pass-Through payment status and a permanent HCPCS code, each effective October 1, 2026, for PYLARIFY TruVu (piflufolastat F18), supporting the Company’s previously announced phased geographic commercial launch.
Received FDA approval for TAUKLARIFY (florquinitau F-18 injection), an F-18-labeled tau PET imaging agent for the evaluation of adults with cognitive impairment being assessed for Alzheimer’s disease. The Company intends to continue supporting Alzheimer’s disease therapeutic programs through its Pharma Solutions business while assessing the appropriate path toward broader commercial availability.
Received final FDA approval for BRAVNETSA (lutetium Lu 177 dotatate), the only radiopharmaceutical the FDA has determined to be bioequivalent and therapeutically equivalent to LUTATHERA for the treatment of adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors; the Company is preparing for a thoughtful commercial launch to support reliable supply and broad patient access.
Dosed the first patient in the SPARROW study, a Phase 2/3 registrational trial evaluating LNTH-2401, the Company’s investigational GRPR-targeted PET imaging agent for prostate cancer; the Phase 3 portion is expected to enroll approximately 400 participants and evaluate diagnostic performance, safety and tolerability.

(Press release, Curium Pharma, NOV 5, 2026, View Source [SID1234674304])